ABSTRACT
Created by digital technology,the Metaverse is a digital platform where the digital virtual world and the actual real world can coexist to some extent. Based on the integration of Metaverse and medical science,this article describes the great development of intelligent medicine in the fields of medical practice,medical education and medical research,especially in the field of surgery. First,the technical source of the Metaverse concept in the field of intelligent medicine can be traced back to technology to generate actual digital data sets from human anatomy. Second,the successful industrial practice of Metaverse in the field of intelligent medicine conforms to the authentic and credible fundamental purpose of "taking people as the first priority and serving people"ï¼ that isï¼ "virtual" must be based on "actual" for "actual".
ABSTRACT
The design, construction and commissioning of a beamline and spectrometer for inelastic soft X-ray scattering at high resolution in a highly efficient system are presented. Based on the energy-compensation principle of grating dispersion, the design of the monochromator-spectrometer system greatly enhances the efficiency of measurement of inelastic soft X-rays scattering. Comprising two bendable gratings, the set-up effectively diminishes the defocus and coma aberrations. At commissioning, this system showed results of spin-flip, d-d and charge-transfer excitations of NiO. These results are consistent with published results but exhibit improved spectral resolution and increased efficiency of measurement. The best energy resolution of the set-up in terms of full width at half-maximum is 108â meV at an incident photon energy tuned about the Ni L3-edge.
ABSTRACT
Cabin emergent depressurization (CED) may occur in spacecraft during manned space flight. The purpose of this paper was to study the combined effects of simulated weightlessness (SW) and CED factors on humans and animals. It was found that the amplitude of T wave of human electrocardiograms (ECG) significantly decreased in bed rest and hypoxia compared with the control condition (P<0.05), and that suspension with pure O2 induced severer edema in the lungs of rats than that in only a pure O2 environment. SW and pure O2 caused middle ear congestion and decreased the barofunction during pressure changes. These results indicate that human response to CED factors become more serious under SW because of the blood redistribution.
Subject(s)
Decompression/adverse effects , Fluid Shifts/physiology , Hypoxia/physiopathology , Lung/pathology , Oxygen/adverse effects , Weightlessness Simulation/adverse effects , Aerospace Medicine , Animals , Barotrauma/etiology , Barotrauma/physiopathology , Bed Rest , Electrocardiography , Humans , Lung/ultrastructure , Male , Microscopy, Electron , Oxygen Inhalation Therapy , Pulmonary Edema/etiology , Pulmonary Edema/physiopathology , Rats , Space SuitsABSTRACT
Objective. To provide related parameters for astronauts. Method. A study of susceptibility to decompression sickness was carried out in 43 subjects in a hypobaric chamber. Result. Incidence of altitude decompression sickness under rest condition was closely related to age, time of oxygen prebreathing, gas bubble formation rates in the venous blood flow returned to heart and some other physiological indexes. Incidence of decompression sickness was significantly higher in subjects aged 30-36 years than in those aged 19-20 years under the same experimental conditions. In the older subjects body-fat, blood cholesterole and noradrenaline in urine during experiment were significantly higher than those in the younger subjects. It also showed that among persons of the same ages, when prebreathing time was longer, the incidence of decompression sickness was significantly lower under the same experimental conditions. Conclusion. It is desirable that the susceptibility to decompression in astronaut be tested with 1 h oxygen prebreathing before exposure to the altitude of 10000 m for 30 min.
Subject(s)
Decompression Sickness/epidemiology , Decompression Sickness/prevention & control , Embolism, Air/epidemiology , Oxygen Inhalation Therapy , Adult , Aerospace Medicine , Age Factors , Altitude , Atmosphere Exposure Chambers , Body Mass Index , Cholesterol/blood , Disease Susceptibility , Embolism, Air/prevention & control , Humans , Incidence , Norepinephrine/urineABSTRACT
A new cucurbitacin with an unusual ring A, isocucurbitacin D 25-O-acetate (1), was isolated from Bolbostemma paniculatum Franguent together with one known compound, cucurbitacin E (2). The structure of new compound was established by spectroscopic methods.
Subject(s)
Cucurbitaceae/chemistry , Triterpenes/isolation & purification , Cucurbitacins , Molecular Structure , Triterpenes/chemistryABSTRACT
Protein prenylation refers to a type of lipid modification in which either a 15-carbon farnesyl or 20-carbon geranylgeranyl isoprenoid is linked via a thioether bond to specific cysteine residues of proteins. The majority of prenylated proteins belong to a group termed "CaaX proteins" that are defined by a specific C-terminal motif that directs their modification by this process. The ménage of CaaX-type prenylated proteins encompasses a wide variety of molecules that are found primarily at the cytoplasmic face of cellular membranes. These include nuclear lamins, Ras and a multitude of GTP-binding proteins (G proteins), several protein kinases and phosphatases, as well as other important proteins. A tremendous number of cellular signaling processes and regulatory events are under the control of CaaX prenyl proteins. While the attached isoprenoid lipids, in general, support the membrane association of the modified proteins, some proteins also clearly participate directly in protein-protein interactions. This chapter will emphasize 1) the biochemistry of the two enzymes termed farnesyltransferase and geranylgeranyltransferase type I, responsible for CaaX protein prenylation, and 2) biological roles for these modifications. Throughout, we will attempt to highlight the significance of prenylation in specific cellular events. The critical importance of this class of lipid modifications is attested to by the emergence of farnesyltransferase as a target for the development of anti-cancer therapeutics.
Subject(s)
Consensus Sequence , Protein Prenylation , Alkyl and Aryl Transferases/metabolism , Farnesyltranstransferase , HumansABSTRACT
Protein farnesyltransferase (FTase) is a zinc metalloenzyme that catalyzes the prenylation of several proteins that are important in cellular regulatory events. A specific residue of FTase, Cys299 in the beta subunit previously identified as essential for zinc binding and catalysis, had been tentatively assigned as one of the zinc ligands. This assignment was subsequently confirmed in the X-ray structure of FTase, which also identified two additional residues, Asp297 and His362 in the beta subunit, as the remaining protein-derived metal ligands. To more fully explore the role of zinc in the catalytic mechanism of FTase, site-directed mutagenesis was performed on these two zinc ligands. Although the abilities of all the mutants to bind the farnesyl diphosphate substrate were similar to that of the wild-type enzyme, all the mutants displayed markedly reduced enzymatic activities and zinc affinities. Steady-state and pre-steady-state kinetic analyses of the residual activities indicated that the rate-limiting step changed from product release in the wild-type enzyme to the chemical step of product formation for three of the mutant enzymes. Additionally, single-turnover experiments indicated that the greatest effect of alteration of zinc ligands for all the mutants was on the product formation step, this being reduced 10(3)-10(5)-fold in the mutant forms compared to the wild-type enzyme. These results confirm a critical involvement of the zinc in catalysis by FTase and support a model in which the metal ion is directly involved in the chemical step of the enzymatic reaction.
Subject(s)
Alkyl and Aryl Transferases/metabolism , Mutation , Zinc/metabolism , Alkyl and Aryl Transferases/biosynthesis , Alkyl and Aryl Transferases/genetics , Animals , Asparagine/genetics , Catalysis , Escherichia coli/metabolism , Farnesyltranstransferase , Histidine/genetics , Kinetics , Ligands , Mutagenesis, Site-Directed , Rats , Recombinant Proteins/biosynthesis , Recombinant Proteins/genetics , Recombinant Proteins/metabolismABSTRACT
Protein farnesyltransferase (FTase) is a zinc metalloenzyme that performs a post-translational modification on many proteins that is critical for their function. The importance of cysteine residues in FTase activity was investigated using cysteine-specific reagents. Zinc-depleted FTase (apo-FTase), but not the holoenzyme, was completely inactivated by treatment with N-ethylmaleimide (NEM). Similar effects were detected after treatment of the enzyme with iodoacetamide. The addition of zinc to apo-FTase protects it from inactivation by NEM. These findings indicated the presence of specific cysteine residue(s), potentially located at the zinc binding site, that are required for FTase activity. We performed a selective labeling strategy whereby the cysteine residues exposed upon removal of zinc from the enzyme were modified with [3H]NEM. The enzyme so modified was digested with trypsin, and four labeled peptides were identified and sequenced, one peptide being the major site of labeling and the remaining three labeled to lesser extents. The major labeled peptide contained a radiolabeled cysteine residue, Cys299, that is in the beta subunit of FTase and is conserved in all known protein prenyltransferases. This cysteine residue was changed to both alanine and serine by site-directed mutagenesis, and the mutant proteins were produced in Escherichia coli and purified. While both mutant proteins retained the ability to bind farnesyl diphosphate, they were found to have lost essentially all catalytic activity and ability to bind zinc. These results indicate that the Cys299 in the beta subunit of FTase plays a critical role in catalysis by the enzyme and is likely to be one of the residues that directly coordinate the zinc atom in this enzyme.
Subject(s)
Alkyl and Aryl Transferases , Cysteine , Transferases/metabolism , Zinc , Chromatography, Ion Exchange , Dimethylallyltranstransferase/chemistry , Dithiothreitol/pharmacology , Ethylmaleimide/pharmacology , Kinetics , Mutagenesis, Site-Directed , Structure-Activity Relationship , Sulfhydryl Reagents/metabolism , Trypsin/metabolismABSTRACT
Protease-activated receptor-1 (PAR1), a G protein-coupled receptor (GPCR) for thrombin, is irreversibly activated by a proteolytic mechanism, then internalized and degraded in lysosomes. The latter is critical for temporal fidelity of thrombin signaling. Toward understanding PAR1 down-regulation, we first investigated the pathway of PAR1 internalization. Activated PAR1 was rapidly recruited to clathrin-coated pits, where it colocalized with transferrin receptor (TfnR). Dominant-negative dynamin and clathrin hub mutants both blocked PAR1 internalization. Blockade of PAR1 internalization with dynamin K44A also inhibited activation-dependent PAR1 degradation. Thus activated PAR1 internalizes via clathrin-coated pits together with receptors that recycle and is then sorted away from such receptors and delivered to lysosomes. In the course of these studies we identified a mutant HeLa cell line, designated JT1, that was defective in PAR1 internalization. PAR1 signaled robustly in JT1 cells but was not phosphorylated or recruited to clathrin-coated pits after activation. Internalization of TfnR was intact in JT1 cells and internalization of beta(2)-adrenergic receptor, a GPCR that internalizes and recycles, was present but perhaps reduced. Taken together, these studies suggest that PAR1 is internalized in a dynamin- and clathrin-dependent manner like TfnR and beta(2)-adrenergic receptor but requires a distinct gene product for recruitment into this pathway.
Subject(s)
Down-Regulation , Mutation , Receptors, Thrombin/metabolism , Adenoviridae/genetics , Cell Line , Cell Membrane/metabolism , Clathrin/agonists , Clathrin/metabolism , Coated Pits, Cell-Membrane/metabolism , DNA, Complementary/metabolism , Dynamins , Enzyme-Linked Immunosorbent Assay , GTP Phosphohydrolases/genetics , GTP Phosphohydrolases/metabolism , Genes, Dominant , HeLa Cells , Humans , Hydrolysis , Immunoblotting , Lysosomes/metabolism , Microscopy, Fluorescence , Phosphorylation , Protein Binding , Receptor, PAR-1 , Receptors, Thrombin/agonists , Receptors, Thrombin/genetics , Receptors, Transferrin/metabolism , Time Factors , TransfectionABSTRACT
Prenylcysteine methyl esters that represent the C-terminal structures of prenylated proteins demonstrate specific substrate-like interactions with P-glycoprotein (Zhang, L., Sachs, C. W., Fine, R. L., and Casey, P. J. (1994) J. Biol. Chem. 269, 15973-15976). The simplicity of these compounds provides a unique system for probing the structural specificity of P-glycoprotein substrates. We have further assessed the structural elements of prenylcysteines involved in the interaction with P-glycoprotein. Carboxyl group methylation, a modification in many prenylated proteins, plays an essential role of blocking the negative charge at the free carboxylate. Substitution of the methyl ester with a methyl amide or simple amide does not change the ability of the molecule to stimulate P-glycoprotein ATPase activity, but substitution with a glycine is not tolerated unless the carboxyl group of glycine is methylated. The presence of a nitrogen atom, which is found in many P-glycoprotein substrates and modifiers, is also essential for prenylcysteines to interact with P-glycoprotein. The structure at the nitrogen atom can, however, influence the type of interaction. Acetylation of the free amino group of prenylcysteine/results in a significant loss in the ability of prenylcysteines to stimulate P-glycoprotein ATPase activity. Instead, certain acetylated prenylcysteines behave as inhibitors of this activity. In studies using MDR1-transfected human breast cancer cells, the acetylated prenylcysteine analogs inhibit P-glycoprotein-mediated drug transport and enhance the steady-state accumulation of [3H]vinblastine, [3H]colchicine, and [3H]taxol. These inhibitors do not, however, affect drug accumulation in parental cells. These studies provide a novel approach for designing P-glycoprotein inhibitors that could prove effective in reversing the phenotype of multidrug resistance in tumor cells.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Cysteine/pharmacology , ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis , Adenosine Triphosphatases/metabolism , Animals , Biological Transport/drug effects , Breast Neoplasms , Cell Line , Cell Membrane/metabolism , Cysteine/analogs & derivatives , Drug Resistance, Multiple/genetics , Female , Humans , Kinetics , Recombinant Proteins/biosynthesis , Recombinant Proteins/metabolism , Spodoptera , Structure-Activity Relationship , Transfection , Tumor Cells, CulturedABSTRACT
Ras proteins are mutationally activated in a variety of human cancers. Since farnesylation of Ras proteins is required for expression of their oncogenic potential, the enzyme responsible for this reaction, farnesyl:protein transferase (FPT), has become a major target for anticancer drug development. FPT is a zinc metalloenzyme, and the zinc is essential for its catalytic activity. To begin to elucidate the role of zinc in catalysis, we initiated metal substitution studies. Of all metals tested, only cadmium was able to functionally substitute for zinc, reconstituting enzymatic activity with native substrates (H-Ras and farnesyl diphosphate) to about 50% of that of the zinc-containing enzyme. Several important differences were observed between cadmium-substituted FPT (Cd-FPT) and zinc-containing FPT (Zn-FPT). Cd-FPT not only uses H-ras with its native CaaX motif (Ras-CVLS) as a substrate but also can farnesylate H-ras in which the CaaX motif is altered to contain a C-terminal leucine residue (Ras-CVLL). Similarly, Cd-FPT can farnesylate leucine-terminated peptides. Leucine-terminated proteins and peptides are usually substrates for the related enzyme geranylgeranyl:protein transferase type I. Farnesylation of Ras-CVLS and Ras-CVLL by Cd-FPT exhibited similar sensitivity to the FPT inhibitor SCH 44342 and to the peptide inhibitor CAIM. However, unlike Zn-FPT, Cd-FPT is also potently inhibited by the leucine-terminated peptide CAIL. These results indicate that the metal ion content of FPT strongly influences its protein substrate specificity.